Updates in the Management of Small Cell Lung Cancer in the Second Line and Beyond

A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.

Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.

A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.